ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- [The guideline for the diagnosis and treatment of marginal zone lymphoma in China (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Guideline
- Diversified cell origin of Helicobacter pylori eradication-responsive gastric diffuse large B-cell lymphomas.The Journal of pathology · 2026Article
- Persistent Hepatitis C Viremia Following Sofosbuvir/Velpatasvir During Bendamustine-Rituximab Therapy for Follicular Lymphoma.Clinical case reports · 2026Article
- The Role of Direct-Acting Antivirals (DAAs) in Hepatitis C Virus-Associated Lymphoproliferative Disorders.Cancers · 2026Review
- Hepatitis C virus and extrahepatic malignancies: where we stand and how we can advance the field.Translational cancer research · 2026Article
- Co-managing the double burden: strategies for simultaneously tackling infectious and non-communicable diseases.Infectious diseases of poverty · 2026Article
- Familial lymphoma and genetic predisposition: an updated review.BMC medical genomics · 2026Review
- Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.British journal of haematology · 2026Article
- Splenic Marginal Zone Lymphoma as a Vascular-Appearing Mass in a Patient With Sustained Virologic Response to Hepatitis C Therapy.The American journal of case reports · 2026Article
- Mechanisms and Therapeutic Strategies for HCV/HBV-Associated B-Cell Non-Hodgkin's Lymphomas: A Viewpoint.Oncology research · 2026Review
- Extranodal Marginal Zone Lymphoma of the Breast in a Patient with Chronic Hepatitis C Infection: A Case Report.Journal of community hospital internal medicine perspectives · 2026Article
- Hepatitis C virus-associated B-cell non-Hodgkin lymphomas: immune evasion, multistep lymphomagenesis, and candidate biomarkers for risk stratification and disease monitoring.Frontiers in immunology · 2026Review
- The Liver in Hematologic Malignancies: Lymphoma, Leukemia, and Myeloma.Clinics in liver disease · 2025Review
- Chronic Hepatitis C Virus Infection, Extrahepatic Disease and the Impact of New Direct-Acting Antivirals.Pathogens (Basel, Switzerland) · 2024Review
- Hepatitis Virus-associated Non-hodgkin Lymphoma: Pathogenesis and Treatment Strategies.Journal of clinical and translational hepatology · 2023Review
- Hepatitis C Virus (HCV)-Ribonucleic Acid (RNA) As a Biomarker for Lymphoid Malignancy with HCV Infection.Cancers · 2023Review
- Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma.Expert review of hematology · 2023Review
- Management of marginal zone lymphomas.Hematology. American Society of Hematology. Education Program · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 18 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe prospectively treated patients with hepatitis C virus (HCV)-associated indolent lymphomas with genotype-appropriate direct-acting antivirals (DAAs) with the aim to evaluate virologic and hematologic outcomes. No prospective studies in this setting have been published so far.
methodsFIL_BArT is a prospective, multicenter, phase II trial that evaluated genotype-appropriate DAAs in untreated HCV-positive patients with indolent lymphomas without criteria for immediate conventional antilymphoma treatment. The primary objective was sustained virologic response, whereas the main secondary objectives were overall response rate of lymphoma and progression-free survival.
resultsForty patients were enrolled, including 27 with marginal zone lymphoma. Median age was 68 years. Extranodal sites were involved in 14 cases (35%). Main genotypes were 1 in 16 patients and 2 in 21 patients. All patients received genotype-guided DAAs: 17 ledipasvir/sofosbuvir, eight sofosbuvir plus ribavirin, and 15 sofosbuvir/velpatasvir. All patients achieved sustained virologic response (100%). DAAs were well tolerated, with only two grade 3-4 adverse events. Overall response rate of lymphoma was 45%, including eight patients (20%) achieving complete response and 10 (25%) partial response, whereas 16 exhibited stable disease and six progressed. With a median follow-up of 37 months, two patients died (3-year overall survival 93%; 95% CI, 74 to 98) and three additional patients progressed, with a 3-year progression-free survival of 76% (95% CI, 57 to 87).
conclusionHCV eradication by DAAs was achieved in 100% of HCV-positive patients with indolent lymphomas not requiring immediate conventional treatment and resulted in non-negligible rate of lymphoma responses. Treatment with DAAs should be considered as the first-line therapy in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.